Sleep loss-induced oncogenic pathways are mediated via the neuron-specific interleukin-1 receptor accessory protein (AcPb).

in Brain, behavior, and immunity by Yool Lee, Erika L English, Catherine M Schwartzmann, Yiyong Liu, James M Krueger

TLDR

  • ELI5: The study investigates how sleep disruption affects brain cancer-related pathways in mice. The study found that sleep disruption increased the levels of a protein called AcPb in the brain, which is involved in cancer and immune responses. The study also found that sleep disruption changed the way genes related to cancer, immune, and viral disease were expressed in the brain. The study also looked at data from a large database of cancer patients and found that certain genes related to sleep and cancer were linked to worse patient outcomes. The study suggests that sleep disruption may promote a pro-tumor environment through AcPb-modulated pathways and identifies sleep-linked factors that significantly impact patient prognosis and survival, particularly in low-grade glioma (LGG) and glioblastoma multiforme (GBM) patients. The study highlights the importance of considering sleep disruption in cancer treatment and prevention. Future research directions could include investigating the role of AcPb in other types of cancer and exploring the potential of AcPb-targeted therapies for cancer treatment. Additionally, further studies could investigate the impact of chronic sleep disruption on cancer-related pathways and patient outcomes.

Abstract

Interleukin-1β (IL1), a pleiotropic cytokine, is involved in sleep regulation, tumor ontogeny, and immune responses. IL1 receptor adaptor proteins, including the IL1 receptor accessory protein (AcP), and its neuron-specific isoform, AcPb, are required for IL1 signaling. The AcPb isoform is resultant from alternate splicing of the AcP transcript. Our previous studies using AcPb null (AcPb) mice characterized its participation in sleep regulation and emergent neuronal/glial network properties. Here, we investigated the impact of acute sleep disruption (SD) on brain cancer-related pathways in wild-type (WT) and AcPbmice, employing RNA sequencing methods. In WT mice, SD increased AcPb mRNA levels, but not AcP mRNA, confirming prior similar work in rats. Transcriptome and pathway enrichment analyses demonstrated significant alterations in cancer, immune, and viral disease-related pathways in WT mice after SD, which were attenuated in AcPbmice including multiple upregulated Src phosphorylation-signaling-dependent genes associated with cancer progression and metastasis. Our RNAseq findings, were analyzed within the context of The Cancer Genome Atlas Program (TCGA) data base; revealing an upregulation of sleep- and cancer-linked genes (e.g., IL-17B, IL-17RA, LCN2) across various tumors, including brain tumors, compared to normal tissues. Sleep-linked factors, identified through TCGA analyses, significantly impact patient prognosis and survival, particularly in low-grade glioma (LGG) and glioblastoma multiforme (GBM) patients. Overall, our findings suggest that SD promotes a pro-tumor environment through AcPb-modulated pathways.

Overview

  • The study investigates the impact of acute sleep disruption (SD) on brain cancer-related pathways in wild-type (WT) and AcPb mice using RNA sequencing methods. The study confirms prior work in rats, showing that SD increases AcPb mRNA levels in WT mice but not AcP mRNA. Transcriptome and pathway enrichment analyses demonstrate significant alterations in cancer, immune, and viral disease-related pathways in WT mice after SD, which are attenuated in AcPbmice. The study also analyzes the findings within the context of The Cancer Genome Atlas Program (TCGA) database, revealing an upregulation of sleep- and cancer-linked genes across various tumors, including brain tumors, compared to normal tissues. Sleep-linked factors identified through TCGA analyses significantly impact patient prognosis and survival, particularly in low-grade glioma (LGG) and glioblastoma multiforme (GBM) patients. The study aims to investigate the role of AcPb in brain cancer-related pathways and its impact on patient prognosis and survival.

Comparative Analysis & Findings

  • The study compares the outcomes observed under different experimental conditions or interventions detailed in the study. The study found that SD increased AcPb mRNA levels in WT mice but not AcP mRNA. Transcriptome and pathway enrichment analyses demonstrated significant alterations in cancer, immune, and viral disease-related pathways in WT mice after SD, which were attenuated in AcPbmice. The study also analyzed the findings within the context of The Cancer Genome Atlas Program (TCGA) database, revealing an upregulation of sleep- and cancer-linked genes across various tumors, including brain tumors, compared to normal tissues. Sleep-linked factors identified through TCGA analyses significantly impact patient prognosis and survival, particularly in low-grade glioma (LGG) and glioblastoma multiforme (GBM) patients. The key findings of the study suggest that SD promotes a pro-tumor environment through AcPb-modulated pathways.

Implications and Future Directions

  • The study's findings suggest that SD promotes a pro-tumor environment through AcPb-modulated pathways. The study identifies sleep-linked factors that significantly impact patient prognosis and survival, particularly in LGG and GBM patients. The study also highlights the importance of considering sleep disruption in cancer treatment and prevention. Future research directions could include investigating the role of AcPb in other types of cancer and exploring the potential of AcPb-targeted therapies for cancer treatment. Additionally, further studies could investigate the impact of chronic sleep disruption on cancer-related pathways and patient outcomes.